Przeciwciała przeciwko dekarboksylazie glutaminianowej w surowicy

Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby

Steidzami nepieciešamas efektīvas metodes COVID-19 slimības trajektoriju prognozēšanai. Šeit ar enzīmu saistītu imūnsorbentu testu (ELISA) un koronavīrusa antigēna mikroelementu (COVAM) analīze uzrādīja antivielu epitopus COVID-19 pacientu (n = 86) plazmā, kuriem bija plašs slimību stāvoklis. Eksperimentos tika identificētas antivielas pret 21 atlikuma epitopu no nukleokapsīda (saukts par Ep9), kas saistīts ar smagu slimību, ieskaitot uzņemšanu intensīvās terapijas nodaļā (ICU), nepieciešamību pēc ventilatoriem vai nāvi.

Svarīgi, ka anti-Ep9 antivielas var noteikt 6 dienu laikā pēc simptomu parādīšanās un dažreiz 1 dienas laikā. Turklāt anti-Ep9 antivielas korelē ar dažādām blakusslimībām un imūnās hiperaktivitātes pazīmēm. Mēs ieviešam vienkārši aprēķināmu slimības riska faktora rādītāju, lai aprēķinātu katra pacienta blakusslimības un vecumu. Pacientiem ar anti-Ep9 antivielām rādītāji virs 3,Zero paredz smagākus slimības iznākumus ar 13,42 varbūtības koeficientu (96,7% specifiskumu).

Rezultāti ir pamats jauna veida COVID-19 prognostikai, lai ļautu agri identificēt un šķirot augsta riska pacientus. Šāda informācija varētu palīdzēt efektīvākai terapeitiskai iejaukšanai. SVARĪBA COVID-19 pandēmija ir izraisījusi vairāk nekā divus miljonus nāves gadījumu visā pasaulē. Neskatoties uz centieniem cīnīties ar vīrusu, šī slimība joprojām pārņem slimnīcas ar smagi slimiem pacientiem.

COVID-19 diagnostiku var viegli veikt, izmantojot daudzas uzticamas testēšanas platformas; tomēr prognostiskā prognozēšana joprojām ir nenotverama. Šajā nolūkā mēs identificējām īsu epitopu no SARS-CoV-2 nukleokapsīda proteīna, kā arī slimības riska faktora rādītāju, pamatojoties uz blakusslimībām un vecumu. Antivielu klātbūtne, kas specifiski saistās ar šo epitopu, kā arī vērtējuma robežvērtība var paredzēt smagus COVID-19 rezultātus ar 96,7% specifiskumu.

Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom

Priekšvēsture / mērķis: Mēs novērtējām sakarību starp seruma alarmīna līmeni un slimības specifiskajiem rādītājiem pacientiem ar anti-neitrofilo citoplazmas antivielu (ANCA) saistīto vaskulītu (AAV).

Pacienti un metodes: Tika izmantoti serumi un dati par 79 pacientiem. AAV specifiskajiem indeksiem tika savākts Birmingemas vaskulīta aktivitātes rādītājs (BVAS), piecu faktoru rādītājs (FFS) un vaskulīta bojājuma indekss (VDI), kā arī četru alarmīnu līmenis (hepatomas atvasināts augšanas faktors, augstas mobilitātes grupas 1. proteīns) , S100A9 un S100A12) tika mērīti, izmantojot ar enzīmu saistītu imūnsorbentu testu. Tika novērtētas asociācijas starp alarminu līmeni, AAV specifiskajiem indeksiem un iekaisuma laboratorijas marķieriem.

Rezultāti: S100A9 līmenis būtiski korelēja ar C-reaktīvo olbaltumvielu līmeni (r = 0,316, p = 0,005) un S100A12 līmenis korelēja ar VDI (r = 0,232, p = 0,040), kas bija konsekventa pacientu apakšgrupā ar mieloperoksidāzi (perinukleārā) ) -ANCA pozitivitāte. Citas asociācijas starp alarminu līmeni un BVAS, FFS un VDI netika atrastas.

Secinājums: seruma S100A12 līmenis bija saistīts ar orgānu bojājumiem AAV, īpaši mieloperoksidāzes (perinukleārās) -ANCA pozitīviem pacientiem.

bernsklepo
bernsklepo

Anti-IGF-IIR antibody

STJ96634 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IIR.

Anti-IGF-IR antibody

STJ98158 100 µl
EUR 234
Description: Mouse monoclonal to IGF-IR.

Anti-IGF-IR antibody

STJ98159 100 µl
EUR 234
Description: Mouse monoclonal to IGF-IR.

Anti-IGF-IR antibody

STJ93647 200 µl
EUR 197
Description: IGF-IR is a protein encoded by the IGF1R gene which is approximately 154,7 kDa. IGF-IR is localised to the cell membrane. It is involved in apoptotic pathways, the GPCR pathway and ERK signalling. It is a receptor tyrosine kinase which mediates actions of insulin-like growth factor 1. The activated protein is involved in cell growth and survival control and is also crucial for tumour transformation and survival of malignant cells. It is formed from two subunits, each of which is comprised of an extracellular alpha-subunit and a transmembrane beta-subunit with intracellular tyrosine kinase activity. IGF-IR is expressed in the nervous system, skin, pancreas, lung and muscle. Mutations in the IGF1R gene may result in insulin-like growth factor 1 resistance. STJ93647 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of IGF-IR protein.

Anti-IGF-IR antibody

STJ93648 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IR.

Anti-IGF-I antibody

STJ93653 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-I.

Anti-IGF-IIR antibody

STJ93654 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IIR.

Anti-IGF-IIR antibody

STJ93655 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IIR.

Anti-IGF-IR antibody

STJ93656 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IR.

Anti-IGF-IR antibody

STJ93657 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IR.

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

anti-IGF-1R (Ab-1280)

LF-PA20229 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Ab-1346)

LF-PA20230 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Ab-1161)

LF-PA20231 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Phospho-Tyr1161)

LF-PA20233 100 ul
EUR 354
Description: Rabbit polyclonal to IGF-1R (Phospho-Tyr1161)

Anti-Rat IGF-1 Antibody

5121-100
EUR 316

Anti-Rat IGF-1 Antibody

5121-30T
EUR 146

Human Salivary IGF(salivary IGF) ELISA Kit

QY-E05383 96T
EUR 361

Anti-IGF-1R (Teprotumumab), Human IgG1 Antibody

A2160-100 100 µg
EUR 510

IGF-1, human

RC216-12 1mg
EUR 376.25

IGF-BP3, human

RC216-12B3 5ug
EUR 104.38

IGF-1, Human

HY-P7018 10ug
EUR 108

IGF-2, Human

HY-P7019 100ug
EUR 360

IGF-BP3, Human

HY-P7020 10ug
EUR 234

IGF-BP5, Human

HY-P7021 50ug
EUR 601

Polyclonal Anti-Rat IGF-1 Antibody

APR00269G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Anti-Rat IGF-1 . This antibody is tested and proven to work in the following applications:

Anti-IGF-1R (Ab-1161) Antibody

A00070-1 100ul
EUR 397
Description: Rabbit Polyclonal IGF-1R (Ab-1161) Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat.

Anti-Phospho-IGF-IR (Y1346) antibody

STJ91187 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1346).

Anti-Phospho-IGF-IR (Y1161) antibody

STJ90298 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1161).

Anti-Phospho-IGF-IIR (S2409) antibody

STJ90923 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IIR (S2409).

Anti-Phospho-IGF-IR (Y1161) antibody

STJ91026 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1161).

anti-IGF-1R (Ab-1165/1166)

LF-PA20232 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Phospho-Tyr1165/Tyr1166)

LF-PA20234 100 ul
EUR 354
Description: Rabbit polyclonal to IGF-1R (Phospho-Tyr1165/Tyr1166)

IGF-II

PR15045CF 50 ug
EUR 278

Human [Arg6] IGF-II

GU020 20 µg
EUR 253

Human [Leu24] IGF-I

ZU020 20 µg
EUR 253

Human [Leu24] IGF-I

ZU100 100 µg
EUR 346

Human [Leu27]IGF-II

TU100 100 µg
EUR 346

Biotinyl Human IGF-I

AQU010 10 µg
EUR 253

Biotinyl Human IGF-I

AQU050 50 µg
EUR 346

Biotinyl Human IGF-I

AQU100 100 µg
EUR 531

Biotinyl Human IGF-I

AQU500 500 µg
EUR 1088

Human [Ala31] IGF-I

AIU020 20 µg
EUR 253

Human [Ala31] IGF-I

AIU100 100 µg
EUR 346

Human IGF-I Protein

abx060791-100ug 100 ug
EUR 467

Human [Leu60] IGF-I

ABU020 20 µg
EUR 253

Human [Leu60] IGF-I

ABU100 100 µg
EUR 346

Human IGF-1 LR3

SP-89927-100 100 ug
EUR 225

IGF-1, human recombinant

P1016-.02 20 µg
EUR 258
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue

IGF-1, human recombinant

P1016-.1 100 µg
EUR 763
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue

IGF-II, human recombinant

P1017-.01 10 µg
EUR 161
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.

IGF-II, human recombinant

P1017-.05 50 µg
EUR 313
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.

IGF-II, human recombinant

P1017-1 1 mg
EUR 1998
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.

rec IGF-I (human)

H-5555.0050 50.0µg
EUR 242
Description: CAS# [67763-96-6]

rec IGF-I (human)

H-5555.0100 100.0µg
EUR 381
Description: CAS# [67763-96-6]

rec IGF-I (human)

H-5555.0500 0.5mg
EUR 1434
Description: CAS# [67763-96-6]

IGF-I, human recombinant

4119-100
EUR 175

IGF-I, human recombinant

4119-1000
EUR 343

IGF-I, human recombinant

4119-10MG
EUR 1529

IGF-I, human recombinant

4119-1G
EUR 41157

IGF-I, human recombinant

4119-20MG
EUR 2328

IGF-I, human recombinant

4119-5000
EUR 958

IGF-I, human recombinant

4119-50MG
EUR 4220

IGF-II, human recombinant

4122-10
EUR 137

IGF-II, human recombinant

4122-1000
EUR 1572

IGF-II, human recombinant

4122-50
EUR 256

IGF-BP1, human recombinant

4717-100
EUR 620

IGF-BP1, human recombinant

4717-1000
EUR 3149

IGF-BP1, human recombinant

4717-25
EUR 256

IGF-BP3, human recombinant

4720-100
EUR 620

IGF-BP3, human recombinant

4720-1000
EUR 3149

IGF-BP3, human recombinant

4720-25
EUR 256

IGF-BP5, human recombinant

4723-100
EUR 620

IGF-BP5, human recombinant

4723-1000
EUR 3149

IGF-BP5, human recombinant

4723-25
EUR 256

IGF-BP2, human recombinant

7165-10
EUR 251

IGF-BP2, human recombinant

7165-50
EUR 936

IGF-BP7, human recombinant

7167-10
EUR 207

IGF-BP7, human recombinant

7167-50
EUR 675

IGF-BP6, human recombinant

7350-20
EUR 370

IGF-2/ Rat IGF- 2 ELISA Kit

ELA-E0051r 96 Tests
EUR 886

Anti-IGF1/Igf I Rabbit Monoclonal Antibody

M00148 100ug/vial
EUR 397
Description: Rabbit Monoclonal IGF1/Igf I Antibody. Validated in WB and tested in Human.

Anti-IGF2/Igf Ii Rabbit Monoclonal Antibody

M00335 100ug/vial
EUR 397
Description: Rabbit Monoclonal IGF2/Igf Ii Antibody. Validated in IF, WB and tested in Human.

Anti-Phospho-IGF-IR (Y1165/Y1166) antibody

STJ90299 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1165/Y1166).

Mouse Anti-Human IGF-1R monoclonal antibody, clone JID716

CABT-L2807-100uL500uL 100 uL, 500 uL
EUR 502

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-100ug

QP5264-100ug 100ug
EUR 363

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-10ug

QP5264-10ug 10ug
EUR 136

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-1mg

QP5264-1mg 1mg
EUR 1261

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-500ug

QP5264-500ug 500ug
EUR 762

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-50ug

QP5264-50ug 50ug
EUR 237

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-100ug

QP8601-ec-100ug 100ug
EUR 408

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-10ug

QP8601-ec-10ug 10ug
EUR 200

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-1mg

QP8601-ec-1mg 1mg
EUR 1632

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-200ug

QP8601-ec-200ug 200ug
EUR 634

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-500ug

QP8601-ec-500ug 500ug
EUR 1060

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-50ug

QP8601-ec-50ug 50ug
EUR 263

Recombinant Human IGF-BP7 Protein

PROTQ16270-2 25ug
EUR 317
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

Human IGF-I monoclonal antibody

MAM1 500 µg
EUR 299

Human IGF-II (Media Grade)

OM001 1 mg
EUR 902

Human IGF-II (Media Grade)

OU100 100 µg
EUR 327

Human IGF-II (Receptor Grade)

FM001 1 mg
EUR 161

Human IGF-II (Receptor Grade)

FU020 20 µg
EUR 299

Human IGF-II (Receptor Grade)

FU100 100 µg
EUR 392

Recombinant Human IGF-II Protein

PROTP01344-1 50ug
EUR 317
Description: The IGFs are mitogenic polypeptide growth factors that stimulate the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar by structure and function to insulin, but have a much higher growth-promoting activity than insulin. IGF-II expression is influenced by placenta lactogen, while IGF-I expression is regulated by growth hormone. Both IGF-I and IGF-II signal through the tyrosine kinase type I receptor (IGF-IR), but, IGF-II can also signal through the IGF-II/Mannose-6-phosphate receptor. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contain N-terminal and C-terminal propeptide regions. Recombinant human IGF-I and IGF-II are globular proteins containing 70 and 67 amino acids, respectively, and 3 intra-molecular disulfide bonds.

Recombinant Human IGF-I Protein

PROTP05019-1 500ug
EUR 317
Description: The IGFs are mitogenic polypeptide growth factors that stimulate the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar by structure and function to insulin, but have a much higher growth-promoting activity than insulin. IGF-II expression is influenced by placenta lactogen, while IGF-I expression is regulated by growth hormone. Both IGF-I and IGF-II signal through the tyrosine kinase type I receptor (IGF-IR), but, IGF-II can also signal through the IGF-II/Mannose-6-phosphate receptor. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contain N-terminal and C-terminal propeptide regions. Recombinant human IGF-I and IGF-II are globular proteins containing 70 and 67 amino acids, respectively, and 3 intra-molecular disulfide bonds.

Recombinant Human IGF-BP1 Protein

PROTP08833-1 25ug
EUR 317
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4 kDa cysteine-rich secreted protein expressed in liver, deciduas, and kidneys and is the most abundant IGF-BP in amniotic fluid. Levels of IGF-BP1 in serum are lowest after food. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, where as nonphosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4 kDa protein consisting of 235 amino acid residues (Isoform A).

Recombinant Human IGF-BP3 Protein

PROTP17936-2 25ug
EUR 317
Description: IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues.

Recombinant Human IGF-BP2 Protein

PROTP18065 20ug
EUR 317
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków

Ar melanomas diferenciāciju saistītais proteīns 5 (MDA5) antivielu pozitīvais dermatomiozīts (DM) parāda unikālas ādas un patoloģiskās iezīmes. Mēs aprakstām divus ar miozītu saistītas ātri progresējošas intersticiālas plaušu slimības (RP-ILD) gadījumus.

Pacientes bija divas sievietes no Keralas, Indijā. Abiem pacientiem bija anti-MDA5 antivielu pozitīvs miozīts. Abiem pacientiem bija RP-ILD bez jebkādām miozīta klīniskām pazīmēm un viņi pakļāvās savai slimībai, neraugoties uz agresīvu ārstēšanu. Anti-MDA5-antivielu pozitīvam DM raksturīga amiopātiska slimība ar strauji progresējošu un letālu ILD.

Przeciwciała przeciwko dekarboksylazie glutaminianowej w surowicy a zaburzenia neurologiczne: kiedy podejrzewać ich związek?

Mērķi: Izpētīt dažādas neiroloģiskas izpausmes ar aizdomām par saistību ar seruma glutamāta dekarboksilāzes antivielām (GAD-Abs), lai labāk raksturotu anti-GAD neiroloģiskos sindromus.

Metodes: Novērošanas retrospektīvais pētījums, kurā tika iekļauti visi pacienti, kuriem La Pazas Universitātes slimnīcas Neiroloģijas nodaļa laika posmā no 2015. līdz 2019. gadam pieprasīja GAD65-Abs titru serumā. GAD-Abs mērīja ar ELISA. Tika pētīti demogrāfiskie dati, neiroloģiskie simptomi, blakusslimības ar cukura diabētu (DM) vai citu autoimūno slimību un GAD-Abs titri. Stingras personas sindroms, ataksija, encefalīts un epilepsija tika uzskatīti par tipiskiem anti-GAD neiroloģiskiem sindromiem un tika salīdzināti ar citām netipiskām izpausmēm.

Rezultāti: Kopumā tika iekļauti 173 pacienti (51,7% vīriešu, vidējais vecums 51,62). Pēdējo 5 gadu laikā pakāpeniski palielinājās seruma GAD-Abs pieprasījumu skaits, īpaši pacientiem ar netipiskām neiroloģiskām izpausmēm. GAD-Abs tika konstatēti 22 pacientu serumā (12,7%); no tiem 15 (68,18%) cieta tipisku anti-GAD sindromu.

DM vai citas orgānspecifiskas autoimūnas slimības klātbūtne paredzēja GAD-AB seropozitivitāti (p <0,001). 6,6% no pieprasītajiem pacientiem ar netipisku sindromu bija GAD-Abs, guess seruma līmenis bija ievērojami zemāks nekā konstatēts pacientiem ar tipisku sindromu (706,67 vs 1430,23 UI / ml; Mann-Whitney U, p = 0,034), un beidzot diagnosticēta cita neiroloģiska slimība.

Secinājums: serumā GAD-Abs reti tika konstatēti pacienti ar klīniskiem fenotipiem, izņemot tos, kas klasiski aprakstīti kā anti-GAD traucējumi, un ar ļoti zemu titru. Tipiskos anti-GAD sindromos ir augsta saslimstība ar DM un citām autoimūnām slimībām, un parasti ir augsts GAD-Abs līmenis serumā.

Podwójne dodatnie wyniki przeciwciał przeciwko β 2 -glikoproteinie I domenie I i przeciw fosfatydyloserynie / protrombinie wzmacniają zarówno zakrzepicę, jak i dodatni wynik przeciwciał anty-ADAMTS

Lai gan ar iegūto trombotisko trombocitopēnisko purpuru (TTP) rodas daži antifosfolipīdu sindromi (APS), saistība starp antifosfolipīdu antivielām (aPL) un anti-ADAMTS13 (anti-a dezintegrīnu un metalloproteāzi ar 1. tipa trombospondīna motīvu, 13. loceklis) paliek nenoteikta.

Mēs pētījām saikni starp augsta riska trombotisko aPL un anti-ADAMTS13 antivielām. Tika iekļauti divi simti trīsdesmit septiņi pacienti ar pozitīvu vilkēdes antikoagulantu un / vai antikardiolipīna antivielu. Tika izmērīti anti-β2GPI (anti-β2-glikoproteīns I), anti-β2GPIdI (anti-β2-glikoproteīna I domēns I), anti-PS / PT (antifosfatidilserīns un protrombīns), ADAMTS13 aktivitāte un anti-ADAMTS13 antiviela.

Divkārša anti-β2GPI un anti-PS / PT pozitivitāte palielināja trombozes risku vairāk nekā trīs reizes un parādīja paaugstinātu anti-ADAMTS13 antivielu pozitivitāti, salīdzinot ar dubultnegatīvo grupu.

Dubultā pozitīvā anti-β2GPIdI un anti-PS / PT parādīja abus efektus vēl vairāk. Lineārajā regresijas analīzē anti-β2GPI un anti-PS / PT dubultā pozitivitāte neatkarīgi ietekmēja antivielu līmeni anti-ADAMTS13 (β = 1,982, P = 0,042).

Mūsu rezultāti atklāja, ka anti-β2GPI vai anti-β2GPIdI un anti-PS / PT dubultā pozitivitāte palielināja ne tikai trombotisko risku, guess arī anti-ADAMTS13 antivielu pozitivitāti, īpaši norādot, ka anti-β2GPIdI parādīja augstāku sinerģisko efektu ar anti-PS / PT.

Mēs iesakām iespējamu anti-ADAMTS13 antivielu saistību ar augstu APS trombotisko risku.

Anti-β2GPI (anti-β2-glikoproteīns I) un anti-PS / PT (anti-fosfatidilserīns un protrombīns) antivielu dubultā pozitivitāte palielināja ne tikai trombotisko risku, guess arī anti-ADAMTS13 (anti-dezintegrīna un metaloproteāzes ar trombospondīna tipa) pozitivitāti 1 motīvs, loceklis 13) antivielas.

Turklāt anti-β2GPIdI (anti-β2-glikoproteīna I domēns I) dubultā pozitivitāte kombinācijā ar anti-PS / PT vēl vairāk paaugstināja gan trombozi, gan anti-ADAMTS13 antivielu pozitivitāti. Tika konstatēts, ka dubultā pozitivitāte β2GPI un anti-PS / PT kā neatkarīgi nozīmīgs faktors anti-ADAMTS13 antivielu līmeņa paaugstināšanai. Mēs iesakām saistību starp anti-ADAMTS13 antivielām un antifosfolipīdu sindroma patofizioloģiju, kas būtu tālāk jāizvērtē.

Add a Comment

Jūsu e-pasta adrese netiks publicēta.